GlassScriptPhysician profile
Traci A Dieckmann
NPI 1881958015
$4,750.12
in general payments reported to CMS, 2019-2025
48 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $499 · 2021: $987 · 2022: $545 · 2023: $701 · 2024: $676 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $565.06 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $464.45 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $431.31 | 2021-2025 | Vraylar, Qulipta |
| Sanofi-Aventis U.S. LLC | $373.59 | 2019-2023 | |
| Amgen INC. | $324.58 | 2019-2025 | Evenity, Prolia, Prolia |
| Otsuka America Pharmaceutical, INC. | $230.89 | 2020-2025 | Rexulti |
| Allergan, INC. | $197.41 | 2019-2020 | |
| Astellas Pharma US INC | $152.31 | 2019-2024 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $151.03 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.17 | 2020-2024 | Synjardy, Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $141.05 | 2019-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $125.62 | 2023-2025 | Ingrezza |
| Lilly USA, LLC | $113.63 | 2020-2025 | Mounjaro, Jardiance |
| Alkermes, INC. | $91.27 | 2023-2025 | Aristada, Lybalvi |
| Dexcom, INC. | $86.91 | 2022-2025 | Dexcom G6 Transmitter |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Dieckmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.